Litigation-weary J&J pulls Baby Powder talc in North America

Johnson and Johnson has opted to withdraw one its iconic products – talc-based Baby Powder – from sale in the US and Canada.

Sanofi builds case for Sarclisa, challenging J&J’s Darzalex

Sanofi is trumpeting new data for its anti-CD38 drug Sarclisa as it tries to capture market share from Johnson & Johnson’s blockbuster Darzalex in the multiple myeloma mark

J&J defends Darzalex with FDA approval for faster dosing

AbbVie, J&J embed Imbruvica deeper in CLL therapy with new a...

J&J lowers 2020 forecast on COVID-19 uncertainty

J&J and US government invest $1 billion in COVID-19 vaccine

Johnson & Johnson has announced plans to team up with the US government to invest more than  $1 billion in a new vaccine against COVID-19, aiming to begin clinical trials by September.<